Development and Assessment of Imperatorin Nanoemulgel for Enhanced Brain Delivery in a Parkinson's-like Model.
Development and Assessment of Imperatorin Nanoemulgel for Enhanced Brain Delivery in a Parkinson's-like Model.
Where did the research take place?
The study site has not been established. Author addresses may differ from where the research occurred.
Bhilai, IN · Author affiliation
Department of Pharmacy, Shri Shankaracharya Institute of Pharmaceutical Sciences and Research, Bhilai, C.G., India.Location evidence
A plain-language reading has not been prepared for this paper yet.
Original abstract
IntroductionThe present research aimed to address the drawbacks of oral conventional therapy for Parkinson's Disease (PD) by developing and testing a site-specific Imperatorin nanoemulgel that might improve upon it through improved brain-targeted delivery and therapeutic effectiveness.MethodsA gel matrix containing carbopol 940 was used to produce imperatorin on a nanoemulsion scale, utilizing high-energy ultrasonication. After the nanoemulgel was made, its encapsulation efficiency, drug content, zeta potential, polydispersity index, and particle size were evaluated. In vivo efficacy was determined in an MPTP-induced PD rat model by means of behavioral testing (rotarod and open-field), biochemical assays (MDA, SOD, TNF-α).ResultsThe optimized nanoemulgel had a particle size of 120 ± 10 nm, a zeta potential of -25.6 ± 2.1 mV, and an encapsulation efficiency of 92.7 ± 1.5%. It had a biphasic release of the drug with cumulative release of 95.6 ± 2.7% after 24 hours. In vitro assays validation assured increased antioxidant and anti-inflammatory activity compared to the control. In vivo, the nanoemulgel improved the motor function profoundly, decreased oxidative stress (MDA: 1.5 nmol/mg), and normalized antioxidant enzyme activity (SOD: 48.5 U/mg), and downregulated inflammation (TNF- α: 12.4 pg/mg) in PD rats.DiscussionThe imperatorin nanoemulgel performed well to enhance the delivery of the drug into the brain, suppressed PD-associated neurodegeneration, and enhanced behavioral and biochemical scores.ConclusionThis preparation holds a potential non-surgical management approach to PD control that justifies further clinical investigation.